TREATMENT RATIONALE AND STUDY DESIGN FOR AN OPEN-LABEL RANDOMIZED PHASE II TRIAL OF GEMCITABINE AND CISPLATIN WITH OR WITHOUT BEVACIZUMAB IN EGFR WILD-TYPE NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER
JOURNAL OF THORACIC ONCOLOGY（2013）
关键词
non-small-cell lung cancer,First-line,Bevacizumab,Study design
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要